{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:36:02Z","timestamp":1790030162192,"version":"4.0.1"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>\n                                 <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic>, including community-associated methicillin-resistant <jats:italic toggle=\"yes\">S. aureus<\/jats:italic>, is an important cause of pediatric bacteremia. Daptomycin is a well-established treatment option for Gram-positive bacteremia in adults, but its safety and efficacy in children require confirmation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This was a randomized (2:1), evaluator-blinded, multicenter, phase 4 clinical trial comparing intravenous daptomycin with standard-of-care (SOC) for treatment of <jats:italic toggle=\"yes\">S. aureus<\/jats:italic> bacteremia in 1- to 17-year-old patients (Clinicaltrials.gov: NCT01728376). Total treatment duration (intravenous followed by oral step-down therapy) was 5\u201342 days. Daptomycin was dosed once daily by patient age: 12\u201317 years, 7\u2009mg\/kg; 7\u201311 years, 9\u2009mg\/kg and 1\u20136 years, 12\u2009mg\/kg. The primary objective was to evaluate daptomycin safety in children who received \u22651 dose; secondary objectives included comparing daptomycin efficacy with SOC (the trial was not designed to confirm noninferiority) and pharmacokinetic analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Fifty-five children were randomized to daptomycin and 27 to SOC (primarily vancomycin or cefazolin); 90% had <jats:italic toggle=\"yes\">S. aureus<\/jats:italic>. In both groups, 15% of patients had drug-related adverse events, primarily diarrhea (4% daptomycin, 8% SOC) and increased creatine phosphokinase (4% daptomycin, 0% SOC). Clinical success (blinded evaluator-assessed complete\/partial resolution of bacteremia signs and symptoms 7\u201314 days after end-of-treatment) rates were similar for daptomycin (88%) and SOC (77%; 95% confidence interval for difference: \u22129% to 31%). Daptomycin plasma levels across age groups were comparable with those in adults receiving daptomycin at 6\u2009mg\/kg.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Once-daily, age-appropriate daptomycin was well tolerated in children with staphylococcal bacteremia; efficacy was comparable with SOC. Daptomycin in age-adjusted doses is a safe treatment alternative in this setting.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000001926","type":"journal-article","created":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T17:39:03Z","timestamp":1517938743000},"page":"893-900","source":"Crossref","is-referenced-by-count":57,"title":["Randomized Multicenter Study Comparing Safety and Efficacy of Daptomycin Versus Standard-of-care in Pediatric Patients With Staphylococcal Bacteremia"],"prefix":"10.1097","volume":"37","author":[{"given":"Antonio C.","family":"Arrieta","sequence":"first","affiliation":[{"name":"Pediatric Infectious Disease, Children\u2019s Hospital of Orange County, Orange, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Bradley","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Rady Children\u2019s Hospital, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myra W.","family":"Popejoy","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mekki","family":"Bensaci","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjana","family":"Grandhi","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Bokesch","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Glasser","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Du","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hernando","family":"Patino","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Kartsonis","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1017\/ice.2014.91","article-title":"Staphylococcus aureus bacteremia in hospitalized children: incidence and outcomes.","volume":"36","author":"Klieger","year":"2015","journal-title":"Infect Control Hosp Epidemiol"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1097\/INF.0000000000000907","article-title":"Staphylococcus aureus bacteremia in children: changes during eighteen years.","volume":"34","author":"Cobos-Carrascosa","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1586\/14787210.2015.1063418","article-title":"Bacteremia in children: epidemiology, clinical diagnosis and antibiotic treatment.","volume":"13","author":"Pai","year":"2015","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s40124-013-0023-7","article-title":"Update on epidemiology and treatment of MRSA infections in children.","volume":"1","author":"David","year":"2013","journal-title":"Curr Pediatr Rep"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/INF.0b013e3181c767b6","article-title":"Clinical and molecular epidemiology of Staphylococcus aureus catheter-related bacteremia in children.","volume":"29","author":"Carrillo-Marquez","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"R6-20230912","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-2477","article-title":"Daptomycin for complicated skin infections: a randomized trial.","volume":"139","author":"Bradley","year":"2017","journal-title":"Pediatrics"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1086\/420818","article-title":"The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.","volume":"38","author":"Arbeit","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/INF.0b013e318160edfc","article-title":"Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections.","volume":"27","author":"Abdel-Rahman","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1097\/INF.0b013e31820fc8e1","article-title":"Single-dose pharmacokinetics and tolerability of daptomycin 8 to 10\u2009mg\/kg in children aged 2 to 6 years with suspected or proved Gram-positive infections.","volume":"30","author":"Abdel-Rahman","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R13-20230912","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/INF.0000000000000318","article-title":"Single-dose pharmacokinetics of daptomycin in pediatric patients 3-24 months of age.","volume":"33","author":"Bradley","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"R16-20230912","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/phar.1872","article-title":"Clinical experience with daptomycin in pediatrics.","volume":"37","author":"Namtu","year":"2017","journal-title":"Pharmacotherapy"},{"key":"R17-20230912","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/INF.0000000000000962","article-title":"Use of daptomycin in critically ill children with bloodstream infections and complicated skin and soft-tissue infections.","volume":"35","author":"Tedeschi","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"R18-20230912","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/jpids\/piw048","article-title":"Clinical effectiveness, safety profile, and pharmacokinetics of daptomycin in pediatric patients: a systematic review.","volume":"5","author":"Karageorgos","year":"2016","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R19-20230912","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/INF.0000000000001121","article-title":"Daptomycin for children in clinical practice experience.","volume":"35","author":"Garazzino","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"R20-20230912","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/INF.0000000000001076","article-title":"Clinical experience with daptomycin for the treatment of Gram-positive infections in children and adolescents.","volume":"35","author":"Syriopoulou","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"R21-20230912","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1097\/INF.0b013e31814523f8","article-title":"Daptomycin therapy for invasive Gram-positive bacterial infections in children.","volume":"26","author":"Ardura","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"R22-20230912","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1086\/600039","article-title":"Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program.","volume":"49","author":"Figueroa","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R23-20230912","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1592\/phco.31.6.527","article-title":"High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study.","volume":"31","author":"Kullar","year":"2011","journal-title":"Pharmacotherapy"},{"key":"R24-20230912","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s11908-014-0429-6","article-title":"High-dose daptomycin therapy for staphylococcal endocarditis and when to apply it.","volume":"16","author":"Smith","year":"2014","journal-title":"Curr Infect Dis Rep"},{"key":"R25-20230912","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1128\/AAC.02967-15","article-title":"Evaluation of daptomycin exposure and efficacy and safety endpoints to support risk-versus-benefit considerations.","volume":"60","author":"Bhavnani","year":"2015","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201809000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T22:30:40Z","timestamp":1694557840000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201809000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001926","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]}}}